Pathogen diversity, immunity, and the fate of infections: lessons learned from Trypanosoma cruzi human–host interactions

LMD Magalhães, KJ Gollob, B Zingales… - The Lancet …, 2022 - thelancet.com
The complexity of host–pathogen interactions often leads to distinct clinical outcomes upon
infection with different pathogen strains. In this Review, we explore the interactions between …

Chagas disease: a silent threat for dogs and humans

J Durães-Oliveira, J Palma-Marques, C Moreno… - International Journal of …, 2024 - mdpi.com
Chagas disease (CD) is a vector-borne Neglected Zoonotic Disease (NZD) caused by a
flagellate protozoan, Trypanosoma cruzi, that affects various mammalian species across …

New global targets for NTDs in the WHO roadmap 2021–2030

A Casulli - PLoS neglected tropical diseases, 2021 - journals.plos.org
The second World Neglected Tropical Diseases (NTDs) Day was celebrated on 30 January
2021. To mark the occasion, the World Health Organization (WHO) launched its roadmap for …

[HTML][HTML] Enlisting the mRNA vaccine platform to combat parasitic infections

L Versteeg, MM Almutairi, PJ Hotez, J Pollet - Vaccines, 2019 - mdpi.com
Despite medical progress, more than a billion people still suffer daily from parasitic
infections. Vaccination is recognized as one of the most sustainable options to control …

Chagas disease in the United States: a call for increased investment and collaborative research

NIA Higuita, NL Beatty, C Forsyth… - The Lancet Regional …, 2024 - thelancet.com
Chagas disease, caused by the protozoan Trypanosoma cruzi, is a highly overlooked
parasitic infection within the United States. It affects an estimated 300,000 individuals, often …

Localized cardiac small molecule trajectories and persistent chemical sequelae in experimental Chagas disease

Z Liu, R Ulrich vonBargen, AL Kendricks… - Nature …, 2023 - nature.com
Post-infectious conditions present major health burdens but remain poorly understood. In
Chagas disease (CD), caused by Trypanosoma cruzi parasites, antiparasitic agents that …

[HTML][HTML] Immunity and vaccine development efforts against Trypanosoma cruzi

LE Rios, JC Vázquez-Chagoyán, AO Pacheco… - Acta tropica, 2019 - Elsevier
Trypanosoma cruzi (T. cruzi) is the causative agent for Chagas disease (CD). There is a
critical lack of methods for prevention of infection or treatment of acute infection and chronic …

[HTML][HTML] Chagas disease vaccine design: the search for an efficient Trypanosoma cruzi immune-mediated control

AE Bivona, AS Alberti, N Cerny, SN Trinitario… - … et Biophysica Acta (BBA …, 2020 - Elsevier
Chagas disease is currently endemic to 21 Latin-American countries and has also become a
global concern because of globalization and mass migration of chronically infected …

[HTML][HTML] Heterologous mRNA-protein vaccination with Tc24 induces a robust cellular immune response against Trypanosoma cruzi, characterized by an increased …

C Poveda, AC Leão, C Mancino, F Taraballi… - Current Research in …, 2023 - Elsevier
Tc24 is a Trypanosoma cruzi-derived flagellar protein that, when formulated with a TLR-4
agonist adjuvant, induces a balanced immune response in mice, elevating IgG2a antibody …

[HTML][HTML] Treatments and the perspectives of develo** a vaccine for Chagas disease

PSG Farani, KM Jones, C Poveda - Vaccines, 2024 - mdpi.com
Chagas disease (CD) treatment and vaccine development are critical due to the significant
health burden caused by the disease, especially in Latin America. Current treatments …